Back to Search Start Over

Marrow transplant studies in dogs with malignant lymphoma.

Authors :
Appelbaum FR
Deeg HJ
Storb R
Self S
Graham TC
Sale GE
Weiden PL
Source :
Transplantation [Transplantation] 1985 May; Vol. 39 (5), pp. 499-504.
Publication Year :
1985

Abstract

Ninety-five dogs with spontaneous malignant lymphoma in chemotherapy-induced remission were treated with total-body irradiation (TBI) and bone marrow transplantation. Among 38 dogs treated with 8.4 Gy delivered at 4 cGy/min, 9 (24%) became long-term disease-free survivors. Ten of the 38 (26%) died of transplant-related complications and the actuarial relapse rate was approximately 65%. Forty animals were treated with higher-dose TBI (13.5 Gy). The higher-dose TBI led to an increased incidence of transplant-related deaths (55% vs. 26%) and did not reduce the actuarial relapse rate. Eight animals were treated with 8.4 Gy at 4 cGy/min, allogeneic marrow from unrelated donors, and posttransplant immunosuppression with methotrexate and cyclosporine. Of 8 animals, 6 died within 2 weeks of transplant of infection and 2 died later of graft-versus-host disease. Finally, 9 dogs were treated with 8.4 Gy at 4 cGy/min, autologous marrow, and posttransplant methotrexate and cyclosporine. Six of these animals died within 2 weeks of transplant. These studies thus demonstrated that dogs with malignant lymphoma in remission can be cured with high-dose TBI and autologous marrow transplantation, that increasing the total dose of TBI led to increased toxicity without a decrease in the relapse rate, and that post-transplant therapy with methotrexate and cyclosporine was poorly tolerated in these animals.

Details

Language :
English
ISSN :
0041-1337
Volume :
39
Issue :
5
Database :
MEDLINE
Journal :
Transplantation
Publication Type :
Academic Journal
Accession number :
3887690
Full Text :
https://doi.org/10.1097/00007890-198505000-00008